FibroGen, a biotech drug developer, underperformed the market so far this year as of August 12, 2025.
1 report, 1 independent
Updated Aug 12
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FibroGen, a biotech drug developer, underperformed the market so far this year as of August 12, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
FibroGen (United States)
company in San Francisco, United States
Nothing else this week.
Coverage
Newest first; wire copies grouped- ZacksFibroGen (FGEN) Reports Q2 Loss, Lags Revenue Estimates FibroGen (FGEN) came out with a quarterly loss of $3.38 per share versus the Zacks Consensus Estimate of a loss of $2.25. This compares to a lo